Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Pretty weak financial results growth rate 1.8% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (14.2%)
  • Dividend yield for the last twelve months 4.0%
  • Free cash flow yield 1.5% (LTM)
  • Share price is 10.2% higher than minimum and 39.1% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (9.3x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.4 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (0.0%)80.93
year average price 98.06  


year start price 126.45 2024-07-07

max close price 128.97 2024-07-11

min close price 73.47 2025-05-14

current price 80.93 2025-07-06
Common stocks: 2 528 810 012

Dividend Yield:  4.0%
FCF Yield LTM: 1.5%
EV / LTM EBITDA: 9.3x
EV / EBITDA annualized: 8.2x
Last revenue growth (y/y):  -1.6%
Last growth of EBITDA (y/y):  +5.2%
Historical revenue growth:  +6.4%
Historical growth of EBITDA:  +22.0%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 204 657
Net Debt ($m): 25 681
EV (Enterprise Value): 230 338
EBITDA LTM ($m): 24 783
EV / LTM EBITDA: 9.3x
Price to Book: 4.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-07-03zacks.com

Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade

2025-07-03zacks.com

MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE

2025-07-02businesswire.com

FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial

2025-07-01seekingalpha.com

Dividend Yield Theory Says Merck Is A Buy

2025-07-01zacks.com

Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?

2025-07-01businesswire.com

Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative - MFFLI Summit in Dubai

2025-06-29seekingalpha.com

Merck: Don't Let Today's Bargain Opportunity Pass You By

2025-06-27seekingalpha.com

Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)

2025-06-27forbes.com

40% Upside For Merck Stock?

2025-06-26zacks.com

Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data